(Q64166868)

7 January 2021

Ubiquitin: structures, functions, mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Basis for a ubiquitin-like protein thioester switch toggling E1–E2 affinity

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Degradation of cell proteins and the generation of MHC class I-presented peptides

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

The proteasome: paradigm of a self-compartmentalizing protease

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

The 26S proteasome: a molecular machine designed for controlled proteolysis

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Conformational constraints in protein degradation by the 20S proteasome

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Structural basis for the activation of 20S proteasomes by 11S regulators

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Regulation of CD8+ T cell development by thymus-specific proteasomes

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Thymoproteasome: probable role in generating positively selecting peptides

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Total synthesis of lactacystin

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Total synthesis of lactacystin and salinosporamide A.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Total synthesis and biological activity of lactacystin, omuralide and analogs

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

A simple stereocontrolled synthesis of salinosporamide A.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

20S proteasome and its inhibitors: crystallographic knowledge for drug development

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Belactosin A, a novel antitumor antibiotic acting on cyclin/CDK mediated cell cycle regulation, produced by Streptomyces sp

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Total synthesis of (+)-belactosin A

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Enantioselective total syntheses of belactosin A, belactosin C, and its homoanalogue

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Proteasome inhibitors: from research tools to drug candidates

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of Spongia sp.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

New polyhydroxy sterols: proteasome inhibitors from a marine sponge Acanthodendrilla sp.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

The total synthesis of proteasome inhibitors TMC-95A and TMC-95B: discovery of a new method to generate cis-propenyl amides

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Epoxomicin, a new antitumor agent of microbial origin

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Fellutamides A and B, cytotoxic peptides from a marine fish-possessing fungus Penicillium fellutanum

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Proteasome inhibition by fellutamide B induces nerve growth factor synthesis

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Potent Inhibitors of Proteasome

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Preliminary studies of new proteasome inhibitors in the tumor targeting approach: synthesis and in vitro cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Bivalency as a principle for proteasome inhibition

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Synthesis of bivalent inhibitors of eucaryotic proteasomes

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Strategies for the inhibition of serine proteases

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Lack of proteasome active site allostery as revealed by subunit-specific inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

LMP2-specific inhibitors: chemical genetic tools for proteasome biology

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Peptidyl vinyl ester derivatives: new class of selective inhibitors of proteasome trypsin-like activity

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Activity-based protein profiling: the serine hydrolases

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Activity-based protein profiling for the functional annotation of enzymes

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Activity-based protein profiling: new developments and directions in functional proteomics.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Activity-based probes as a tool for functional proteomic analysis of proteases.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Cell surface engineering by a modified Staudinger reaction

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Activity-based protein profiling in vivo using a copper(i)-catalyzed azide-alkyne [3 + 2] cycloaddition

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Profiling proteasome activity in tissue with fluorescent probes

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Acetylene functionalized BODIPY dyes and their application in the synthesis of activity based proteasome probes

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Azido-BODIPY acid reveals quantitative Staudinger-Bertozzi ligation in two-step activity-based proteasome profiling

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

The potential of proteasome inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Proteasome inhibitors in cancer therapy: lessons from the first decade

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Approval summary for bortezomib for injection in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Bortezomib for the treatment of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias.

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021

Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits

1 reference

https://api.crossref.org/works/10.1002%2FEJOC.200900075

7 January 2021